Considerations for Novel COVID-19 Mucosal Vaccine Development
Mucosal surfaces are the first contact sites of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Most SARS-CoV-2 vaccines induce specific IgG responses but provide limited mucosal immunity. Cytokine B-cell activation factor (BAFF) and A proliferation-inducing ligand (APRIL) in the t...
Tallennettuna:
| Päätekijä: | |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI AG
2022-07-01
|
| Sarja: | Vaccines |
| Aiheet: | |
| Linkit: | https://www.mdpi.com/2076-393X/10/8/1173 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|